FINRA's Examination Findings & Priorities
A Look Back & What to Expect in 2018
31 January 2018
The Financial Industry Regulatory Authority (FINRA) recently issued its Report on Examination Findings, as well as its 2018 Regulatory and Examination Priorities Letter. Combined, these two reports provide insight into several broad policy issues that FINRA believes should be key points of emphasis for member firms in 2018. What are these points and how will they affect your business?
In this in-depth webinar, Foley attorneys Dean Jeske, Allison Charney, and Joe Edmondson take a closer look at the following topics:
- A Brief Review of the FINRA360 Initiative: What’s Changed & What Does it Mean?
- Examining FINRA’s 2018 Exam Findings and the Exam Priorities Letter: What’s new? What are the biggest risks?
- Learning the Hidden Nuances That Could Prove Invaluable to Your Exam Preparation.
If you have questions or would like more information, please contact Kayla Huven at [email protected].
Recording
People
Related Insights
20 December 2024
Health Care Law Today
GLP-1 Drugs: FDA “Re-Confirms” Decision Removing Tirzepatide from the Drug Shortage List
On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a Declaratory Order reevaluating and re-confirming that the tirzepatide drug shortage has been resolved. This order revoked and replaced FDA’s October 2, 2024, decision on tirzepatide.
20 December 2024
Manufacturing Industry Advisor
Christmas Came Early: Justice Delivered in Supplier Dispute Over Unjust Enrichment
The AirBoss saga continues… This holiday season, AirBoss Flexible Products Co. received a monumental legal victory, righting a costly wrong in MSSC, Inc. v. AirBoss.
19 December 2024
Health Care Law Today
HIPAA Reproductive Health Care Amendments: Compliance in an Uncertain Enforcement Landscape
The amendments to the HIPAA Privacy Rule designed to protect reproductive health care information are under legal challenge as the compliance date quickly approaches.